Hair Cloning and Follicle Multiplication: Where the Research Stands

Hair cloning has been called the holy grail of hair loss treatment for over two decades. The concept is simple: take a few healthy hair follicles from a patient, multiply the follicle-forming cells in a lab, and reimplant them to grow an unlimited number of new hairs. If it worked, it would make donor scarcity obsolete and render traditional hair transplants a relic of an older era. The problem is that dermal papilla cells, the master regulators of follicle formation, lose their ability to induce new hairs once they are cultured outside the body. Solving this single problem has consumed entire research careers. Here is an honest look at where the science stands, who is working on it, and what the realistic timeline looks like. In the meantime, BaldingAI lets you track the treatments that are available now with objective density measurements over time.

What does “hair cloning” actually mean?

The term “hair cloning” is used loosely in popular media, but in the research literature the more precise terms are follicle neogenesis (creating entirely new follicles) and dermal papilla cell multiplication (expanding the signaling cells that instruct follicle formation). Both aim to solve the same constraint: a person with androgenetic alopecia has a finite number of DHT-resistant follicles in the donor area, and current hair transplant techniques simply redistribute those follicles.

True hair cloning would involve taking a small biopsy of scalp tissue, isolating dermal papilla cells, expanding them in culture to produce millions of copies, and then injecting or implanting those cells into bald or thinning areas where they would interact with the local epithelium to generate fully functional hair follicles. Each new follicle would cycle through anagen, catagen, and telogen just like a natural hair, producing visible terminal hairs through the normal hair growth cycle.

Why has hair cloning been so difficult?

The central technical barrier is the loss of inductivity. Dermal papilla cells freshly isolated from a human follicle express a specific gene signature, including versican, alkaline phosphatase, SOX2, WNT5A, and BMP6, that enables them to signal to neighboring epithelial cells and initiate follicle morphogenesis. When these cells are placed in standard 2D monolayer culture on plastic dishes, they rapidly lose this signature within two to three passages. They flatten, spread, and begin to resemble generic fibroblasts. They proliferate readily, but they can no longer instruct hair follicle formation.

This was demonstrated clearly by Ohyama et al. (2012), published in the Journal of Investigative Dermatology, which showed that serial passaging of human DP cells leads to progressive downregulation of Wnt pathway genes and loss of alkaline phosphatase activity. The cells are alive and multiplying, but they have forgotten how to be dermal papilla cells. The challenge is not growing more cells. The challenge is growing more cells that still function as DP cells.

This problem is related to the broader biology of follicular miniaturization. In vivo, DP cell number and signaling capacity decline as follicles miniaturize under the influence of dihydrotestosterone. The lab culture problem mirrors, in accelerated form, what happens on a balding scalp over years.

Key breakthroughs in follicle neogenesis

3D spheroid culture (Higgins et al. 2013). The most cited advance came from Angela Christiano's lab at Columbia University. Higgins et al. (2013), published in the Proceedings of the National Academy of Sciences, demonstrated that culturing human DP cells as 3D spheroids (self-aggregated cell clusters in hanging drops) partially restored the transcriptional signature of intact dermal papillae. When these spheroids were transplanted between the dermis and epidermis of human foreskin tissue grafted onto immunodeficient mice, they induced new hair follicle formation in five of seven cases. This was the first demonstration that cultured human DP cells could induce de novo follicles in a human tissue context.

The study had limitations. The newly induced follicles were small, the efficiency was variable, and the experiment used neonatal foreskin as the recipient epithelium, which is more responsive than adult scalp skin. But the proof of concept was significant: 3D architecture preserves something critical about DP cell identity that 2D culture destroys.

Bioengineered follicle germs (Toyoshima et al. 2012). Takashi Tsuji's group at RIKEN in Japan took a different approach. Toyoshima et al. (2012), published in Nature Communications, created bioengineered hair follicle germs by combining epithelial and mesenchymal cells in a collagen gel. When transplanted into nude mice, these germs generated fully functional follicles that cycled repeatedly, produced pigmented hairs, and connected to surrounding arrector pili muscles and nerve fibers. The follicles responded to hair-cycle-dependent depilation, confirming functional cycling.

This work demonstrated that reconstituted follicle germs can produce structurally complete, cycling follicles in an animal model. The translation challenge is enormous: the cells used were murine, the recipient environment was immunodeficient mouse skin, and the protocol is far too labor-intensive for clinical-scale production.

Organoid and scaffold approaches. More recent work has explored growing DP cells on biomaterial scaffolds or in organoid systems that better mimic the dermal papilla microenvironment. Lee et al. (2020) used polyethylene glycol hydrogels to maintain DP cell spheroids and reported improved retention of inductive markers compared to standard culture. Kageyama et al. (2022), from Tsuji's group, published methods for generating hair follicle organoids from mouse pluripotent stem cells that self-organized into follicle-like structures in culture. These organoid approaches remain preclinical but represent a shift toward scalable manufacturing.

Companies working on hair cloning

dNovo. Founded by Karl Koehler (formerly at Indiana University, now at Boston Children's Hospital/Harvard), dNovo is developing skin organoid technology that generates hair follicles from pluripotent stem cells. Their approach grows entire skin constructs in vitro that spontaneously form follicles during development. The company has raised venture funding and is working toward clinical translation, though no human trials have been announced.

Stemson Therapeutics. Co-founded by Alexey Terskikh (Sanford Burnham Prebys) and working with Angela Christiano as a scientific advisor, Stemson uses iPSC-derived DP cells combined with proprietary scaffold technology. Their published work in mice showed human iPSC-derived DP cells generating hair follicles when implanted with appropriate epithelial cells. The company has been pursuing a pathway toward human trials, though specific timelines have not been publicly confirmed.

Other groups at academic institutions in Japan (RIKEN/Organ Technologies), South Korea (Yonsei University), and the UK (Durham University) continue active research programs. The field is small enough that a single breakthrough in maintaining DP cell inductivity at scale could rapidly change the timeline.

What about Intercytex and earlier attempts?

The history of hair cloning includes a cautionary tale. Intercytex, a UK-based company, conducted a small Phase II trial in the mid-2000s using cultured DP cells injected into balding scalps. The trial reportedly showed new hair growth in some patients, but the results were modest, highly variable, and the company eventually folded without advancing to Phase III. The likely reason: the cultured DP cells had partially lost inductivity during expansion, producing inconsistent outcomes. This underscored the fundamental technical challenge that the field is still working to solve.

Realistic timeline

Anyone telling you hair cloning will be available in two to three years is either misinformed or selling something. The honest assessment: initial human proof-of-concept trials for iPSC-derived or organoid-based approaches are plausible within 3 to 5 years. A treatment that is scalable, reproducible, affordable, and FDA-approved is more likely 10 to 15 years away. The manufacturing challenge alone, producing billions of functional DP cells per patient under GMP conditions, is a problem that no group has solved yet.

Regulatory requirements add further time. Any cell-based therapy will need to demonstrate safety (no tumor formation, no uncontrolled growth, no immune rejection), efficacy in randomized controlled trials, and manufacturing consistency. Each of these phases takes years.

Why tracking current treatments matters

Hair cloning is not here yet. What is here: finasteride, dutasteride, minoxidil, PRP, low-level laser therapy, and hair transplant surgery. These treatments cannot create new follicles, but they can preserve existing ones and, in many cases, partially reverse miniaturization. The goal is to maintain as much follicular infrastructure as possible so that when cell-based therapies do arrive, your scalp is a viable recipient.

BaldingAI gives you a way to objectively measure whether your current regimen is holding the line. Consistent photo tracking over 12-week windows produces density trend data that you and your dermatologist can use to make informed decisions. A stable or improving trend means your protocol is working. A declining trend means it may be time to add or change an intervention. Either way, you have data instead of guesswork.

The bottom line

Hair cloning is not science fiction. Real researchers at well-funded institutions are making incremental but meaningful progress on the core problem of maintaining dermal papilla cell inductivity outside the body. The 3D spheroid breakthrough from Higgins et al. and the bioengineered follicle work from Toyoshima et al. proved that the concept is biologically feasible. But translating these findings into a treatment you can receive at a clinic remains a formidable engineering, manufacturing, and regulatory challenge.

The best strategy today is a dual one: stay informed about research developments, and use proven treatments to preserve the follicles you still have. When hair cloning does arrive, the patients who benefit most will be those who maintained their follicular health in the years before it became available.

Preserve what you have while science catches up

BaldingAI tracks your density over time so you know whether your current treatment is working while you wait for the next generation.

Your scans stay private. Delete or export anytime.

Sources: Higgins et al. 2013, Proceedings of the National Academy of Sciences, Toyoshima et al. 2012, Nature Communications, Ohyama et al. 2012, Journal of Investigative Dermatology.